the modification that turned minutes into days
1982 (GHRH itself isolated) / 2005–2006 (CJC-1295 with DAC developed and published)
The DAC modification took growth hormone-releasing hormone's natural half-life — about seven to ten minutes — and stretched it to six to eight days, by chemically hijacking a ride on the same albumin protein that ferries fatty acids through your bloodstream.
For two decades, scientists hunted a hormone in the wrong body part. Since the early 1960s, when Seymour Reichlin's lesion experiments in rats hinted that a growth hormone-releasing hormone (GHRH) must live in the hypothalamus, researchers kept trying to extract it straight from brain tissue — and kept failing, because a normal hypothalamus makes vanishingly tiny amounts of the stuff. The breakthrough arrived from an almost absurd side door: patients with acromegaly whose pancreatic tumors were, by pure pathological accident, pumping out ectopic GHRH in industrial quantities. In 1982, two competing teams — Roger Guillemin (already a 1977 Nobel laureate) with Jean Rivier, and Wylie Vale with Rivier, Joachim Spiess, and Michael Thorner at the Salk Institute — independently isolated and sequenced GHRH not from a brain, but from tumor tissue cut out of two separate patients. One yielded a 44-amino-acid form, the other a 40-residue version; both matched the hypothalamus's own hormone exactly.
There was just one problem: native GHRH is a terrible drug. Injected into the body, the kidneys clear it and enzymes shred it within seven to ten minutes — useless outside a hospital infusion pump. Enter ConjuChem, a Montreal biotech firm that in the early 2000s had built a platform called DAC (Drug Affinity Complex) for exactly this kind of half-life problem. The trick: attach a small reactive linker to the peptide so that, once injected, it covalently latches onto cysteine-34 on circulating serum albumin — the same abundant blood protein that shuttles fatty acids around and stays in circulation for roughly two weeks. Hitch a permanent ride on albumin, and the peptide inherits albumin's slow clearance.
Bolt that DAC tail onto a fragment of GHRH(1-29) and you get CJC-1295 ("CJC" for ConjuChem, 1295 an internal compound number). In human data published by Sam Teichman and colleagues in the Journal of Clinical Endocrinology & Metabolism in 2006, a single subcutaneous shot produced 2- to 10-fold jumps in growth hormone lasting six or more days, with IGF-1 elevated for nine to eleven days. Strip off the DAC tail and you get a very different animal — the shorter-acting CJC-1295 no DAC (also called Mod GRF 1-29), which behaves much like native GHRH with a half-life of about 30 minutes, a distinction the peptide-vendor world routinely blurs.
ConjuChem pushed the DAC version into Phase II trials for a genuinely sympathetic target: HIV-associated lipodystrophy, the disfiguring fat redistribution that plagued long-term antiretroviral patients. Then, in July 2006, the 192-person, placebo-controlled trial was halted abruptly after a participant at a study site in Argentina died. The company halted development as a precaution, though the attending physician ultimately attributed the death to the participant's pre-existing coronary artery disease rather than the drug. Clinical development of CJC-1295 with DAC never resumed — it never reached FDA approval and is formally an abandoned drug candidate.
The heart of this story checks out: the accidental discovery of GHRH in acromegaly patients' pancreatic tumors, the albumin-hijacking DAC chemistry, the dramatic half-life stretch, and the 2006 trial halt in Argentina are all independently corroborated. One small name error crept in, though — the second discovery team's scientist was Wylie Vale of the Salk Institute, not "Peter Vale" (there is no Peter Vale in this history), which is why we've flagged the piece as embellished rather than solid.
CJC-1295 with DAC never became an approved medicine — it's a shelved Phase II candidate, frozen in regulatory limbo after ConjuChem walked away in 2006. That limbo is exactly what let it slip into the research-chemical, anti-aging clinic, and bodybuilding/biohacking markets it's known in today, almost always discussed alongside its shorter-acting sibling (CJC-1295 no DAC / Mod GRF 1-29) and frequently paired with the ghrelin-mimetic ipamorelin. In the US, the FDA has repeatedly moved it on and off its interim pharmacy-compounding lists — most recently pulling it from Category 2 in 2024, with further review running through 2026 — so its legal footing stays unsettled. For competitive athletes the line is clear: both forms sit on WADA's Prohibited List under S2, banned at all times.
